Navigation Links
Advinus Therapeutics, a TATA Enterprise, Meets Year 1 Milestone in Drug Discovery Alliance

PUNE, India, January 7, 2014 /PRNewswire/ --

Advinus Therapeutics Ltd., the TATA promoted Pharmaceutical R&D Company, announced today that it has received the first year milestone in its Research and Development Collaboration with Takeda Pharmaceutical Company Limited. The achievement of this milestone underscores the success of the collaboration and also provides validation of Advinus' capabilities in innovative Drug Discovery and Takeda's confidence in these capabilities. As a consequence, a payment of $ 3 M will be made by Takeda to Advinus to mark the achievement.

In October 2012, Advinus and Takeda announced a multi-year multi-project collaboration in the area of drug discovery. In this collaboration, Advinus is responsible for carrying out all the research required to identify candidate molecules for clinical development in several therapeutic areas while Takeda is responsible for the development and commercialization of these candidates.

"Achievement of the rather challenging first year milestone can be attributed to the truly collaborative nature of our relationship with Takeda as well as Advinus' young talent's ability to solve complex problems with efficiency and speed",  said Kasim Mookhtiar, CSO of Advinus.

About Advinus

Advinus Therapeutics is a research based Pharma Company founded by global Pharma executives and promoted by the TATA group. The company is the first of its kind in India to offer end to end development services to the global Pharma, Agro and Biotech industry while creating long term value through internal and collaborative Drug Discovery. The primary focus of the company's discovery efforts are in Metabolic Diseases, Inflammatory Diseases and Pain/ Neurodegeneration. Advinus also has an interest in pursuing the discovery of novel therapies for neglected or developing world diseases. Advinus' drug development operations supports and supplements the client resources at increased levels of cost-efficiency by providing services in the areas of Process Development, Drug Metabolism and Pharmacokinetics, Clinical Pharmacology, Safety Assessment, Formulation Development and Analytical R&D. For company information, visit Advinus at

Joshua Daniel
Corporate Communications

SOURCE Advinus Therapeutics Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
2. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
3. Boston Therapeutics, Inc. Investor Presentation Now Available for On-demand Viewing at
4. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
5. Dual Chamber Syringes & Injectors. Devices, Therapeutics, Markets and Forecasts
6. Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics
7. Inhibikase Therapeutics, Inc. Elects Anthony Zook To The Board Of Directors
8. Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
9. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
10. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.
11. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
Post Your Comments:
(Date:11/26/2015)... , 26 november 2015 AAIPharma ... de geplande investering aan van ten minste ... laboratoria en het mondiale hoofdkantoor in ... zal resulteren in extra kantoorruimte en extra ... de groeiende behoeften van de farmaceutische en ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
(Date:11/26/2015)... 26, 2015 ... ser potential att använda SyMRI för att ... för patienter med multipel skleros (MS) eller ... SyntheticMR AB för att kunna använda SyMRI ... Med SyMRI kan man generera flera konstrastbilder ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... were," said an inventor from Hillside, N.J. "Many people catch diseases simply from ... that individuals will always be protected from germs." , He developed the patent-pending ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
Breaking Medicine News(10 mins):